Apnimed, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APMD research report →
Range $60 – $60
Price Chart
About the company
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction.
- CEO
- Kevin R. Lind
- IPO
- 2026
- Employees
- 81
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on APMD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $669.84M
- P/E
- 3.83
- PEG
- 0.04
- P/S
- 7.50
- P/B
- 1.72
- EV/EBITDA
- 17.16
- Div Yield
- 0.00%
- Gross Margin
- 96.52%
- Op Margin
- 24.91%
- Net Margin
- 172.13%
- ROE
- 136.65%
- ROIC
- 7.21%
Latest fiscal year · YoY change
- Revenue
- $38.47M+0.0%
- Gross Profit
- $31.77M+0.0%
- Op Income
- $-53,818,000
- Net Income
- $-932,000+0.0%
- EPS
- $-0.03+0.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $35.29
- 52W Low
- $13.88
- 50D MA
- $19.67
- 200D MA
- $22.72
- Beta
- 7.95
- RSI (14)
- 43
- Avg Volume
- 458.53K
No earnings-call transcripts are available for APMD yet.
- Free Float
- 8.1%
- Shares Outstanding
- 41.63M
- Float Shares
- 3.37M
of shares held by institutions
12 13F filers
Buy/sell ratio 1.32. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Janus Henderson Group Ltd. | 1.56M | ▲ 1.56M |
| Nexpoint Asset Management, L.P. | 1.27M | ▲ 1.27M |
| Logos Global Management LP | 1.10M | ▲ 1.10M |
| Orbimed Advisors LLC | 925.00K | ▲ 925.00K |
| Alliancebernstein L.P. | 580.28K | ▲ 580.28K |
| Citadel Advisors LLC | 517.65K | ▲ 517.65K |
| Masters Capital Management LLC | 125.00K | ▲ 125.00K |
| Ghisallo Capital Management LLC | 125.00K | ▲ 125.00K |
| Schonfeld Strategic Advisors LLC | 21.64K | ▲ 21.64K |
| D. E. Shaw & Co., Inc. | 10.40K | ▲ 10.40K |
| Price T Rowe Associates Inc | 10.17K | ▲ 10.17K |
| Bellevue Group AG | 4.92K | ▲ 4.92K |
Held by 105 ETFs
Biggest fund positions in APMD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 3, 26 | Morningside Venture Investments Ltd | buy | 312,500 |
| Aug 3, 26 | Morningside Venture Investments Ltd | other | 6,840,213 |
| Aug 3, 26 | Morningside Venture Investments Ltd | other | 6,840,213 |
| Aug 3, 26 | Morningside Venture Investments Ltd | other | 75,624 |
| Aug 3, 26 | Morningside Venture Investments Ltd | other | 75,624 |
| Aug 3, 26 | Morningside Venture Investments Ltd | other | 75,624 |
| Aug 3, 26 | Morningside Venture Investments Ltd | other | 1,088,986.3 |
| Aug 3, 26 | Morningside Venture Investments Ltd | other | 9,227,454 |
| Aug 3, 26 | Morningside Venture Investments Ltd | other | 6,840,213 |
| Aug 3, 26 | Alpha Wave Ventures GP, Ltd | other | 1,512,480 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our APMD coverage
Recent articles, reports, and earnings notes.
Want a deeper read on APMD?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
New National Survey Found Many People With Sleep Apnea Struggle to Stay on Treatment
globenewswire.com · Nov 19
Apnimed Reports Third Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Nov 16
Apnimed: Top Pick Biotech, Treating OSA With A Pill, Initiating With A Buy
seekingalpha.com · Nov 12
Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 5
Apnimed to Present Five Abstracts, Including Two Late-Breakers at CHEST 2026
globenewswire.com · Oct 12
Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Oct 2
Apnimed, Inc. (NASDAQ:APMD) Stock Short Interest Jumps 55.7%
defenseworld.net · Oct 1
Apnimed, Inc. (NASDAQ:APMD) Given Consensus Rating of “Moderate Buy” by Brokerages
defenseworld.net · Sep 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
